FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BENEFICIA	L OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	urden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Mitrano Richard J. (Last) (First) (Middle) C/O FREQUENCY THERAPEUTICS, INC., 75 HAYDEN AVE, SUITE 300				2. Issuer Name and Ticker or Trading Symbol Frequency Therapeutics, Inc. [FREQ] 3. Date of Earliest Transaction (Month/Day/Year) 08/17/2022									Director Officer (below)	tionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner Officer (give title below) VP Finance & Operations				
(Street) LEXING	TON M	1A State)	02421 (Zip)	Dorive	If Amendment, Date of Original Filed (Month/Day/Year) Acquired, Disposed of, or Benefice							Line	Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Transa Date				action 2A. Deemed Execution Date, if any		3. Transaction Code (Instr. 2)		(A) or	5. Amoun	Form Sollowing (I) (I)		Direct I Indirect I str. 4)	7. Nature of ndirect Beneficial Ownership (Instr. 4)					
									Code	v	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				
			Table II - I								sed of, convertible			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Co	ansaction De ode (Instr. Se Ac Di (D		Derivative		6. Date Exercisable a Expiration Date (Month/Day/Year)		te	of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
				Cod	de V	(4	A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)	(s)	
Stock Option	\$2.14	08/17/2022		A		1'	7,816		(1)		10/01/2029	Common Stock	17,816	(2)	17,81	6	D	
Stock Option	\$14	08/17/2022		D				17,816	(1)		10/01/2029	Common Stock	17,816	(2)	0		D	
Stock Option	\$2.14	08/17/2022		A		13	8,000		(3)		02/11/2030	Common Stock	18,000	(2)	18,00	0	D	
Stock Option	\$25.05	08/17/2022		D				18,000	(3)		02/11/2030	Common Stock	18,000	(2)	0		D	
Stock Option	\$2.14	08/17/2022		А		1	1,550		(4)		01/14/2031	Common Stock	11,550	(2)	11,550	0	D	
Stock Option	\$35.85	08/17/2022		D	T^{-}			11,550	(4)		01/14/2031	Common Stock	11,550	(2)	0		D	

Explanation of Responses:

- 1. The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023.
- 2. The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.
- 3. The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024.
- 4. The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025.

/s/ James Abely, Attorney-in-Fact for Richard Mitrano

08/19/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.